2024
Reproducibility for quantification of myocardial Tc-99m PYP amyloid uptake in grade 1 patients
Sandoval V, Goyal D, Miller E, Liu Y. Reproducibility for quantification of myocardial Tc-99m PYP amyloid uptake in grade 1 patients. European Heart Journal - Cardiovascular Imaging 2024, 25: jeae142.047. DOI: 10.1093/ehjci/jeae142.047.Peer-Reviewed Original ResearchStandardized uptake valueTc-99m PYP uptakeTc-99Cardiac amyloidosisHeart failureStandard uptake value quantificationStandardized uptake value calculationSPECT imagesIntractable heart failureSystolic heart failureIntroduction of therapyPlanar imagingTc-99m pyrophosphateAmyloid patientsSPECT/CT imagingInter-reproducibilityUptake valueContralateral ratioCoefficient of variationDisease progressionH/M ratioGrade 1Blood poolPatientsH/CL ratio
2023
Current Landscape and Future Directions of Coronary Revascularization in Ischemic Systolic Heart Failure: A Review
Chuy K, Velazquez E, Lansky A, Jamil Y, Ahmad Y. Current Landscape and Future Directions of Coronary Revascularization in Ischemic Systolic Heart Failure: A Review. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101197. PMID: 39131064, PMCID: PMC11307589, DOI: 10.1016/j.jscai.2023.101197.Peer-Reviewed Original ResearchIschemic systolic heart failureSystolic heart failurePercutaneous coronary interventionHeart failureMedical therapyCoronary revascularizationBenefits of PCITrials of PCILeft ventricular systolic dysfunctionPrevalence of HFBenefit of CABGContemporary medical therapyIschemic ventricular dysfunctionCoronary artery bypassVentricular systolic dysfunctionCoronary artery diseaseIschemic heart diseaseAcute cardiac careComparative clinical effectivenessUnmet clinical needRecent revascularizationArtery bypassSystolic dysfunctionVentricular dysfunctionCoronary interventionQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
2019
Contemporary personalized β-blocker management in the perioperative setting
Oprea AD, Wang X, Sickeler R, Kertai MD. Contemporary personalized β-blocker management in the perioperative setting. Journal Of Anesthesia 2019, 34: 115-133. PMID: 31637510, DOI: 10.1007/s00540-019-02691-9.Peer-Reviewed Original ResearchConceptsPerioperative β-blocker useΒ-blocker useMajor postoperative cardiac eventsPost-acute myocardial infarctionCardiac adverse eventsPostoperative cardiac eventsSystolic heart failureBeta-adrenergic blockersLong-term treatmentCase-based reviewAdverse eventsCardiac eventsPerioperative periodPerioperative useCardiac surgeryHeart failureMyocardial infarctionPerioperative settingEarlier small-scale studiesTrialsEvaluation trialsPotential benefitsNoncardiacEarlier findingsInfarction
2018
Letter by Adabag et al Regarding Article, “Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure”
Adabag S, Wininger M, Singh SN. Letter by Adabag et al Regarding Article, “Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure”. Circulation 2018, 137: 2188-2189. PMID: 29760231, DOI: 10.1161/circulationaha.117.032906.Peer-Reviewed Case Reports and Technical Notes
2016
Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support
Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, Ilkayeva OR, Bowles DE, Patel CB, Milano CA, Rogers JG, Felker GM, O’Connor C, Shah SH, Kraus WE. Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. Journal Of The American College Of Cardiology 2016, 67: 291-299. PMID: 26796394, PMCID: PMC5429585, DOI: 10.1016/j.jacc.2015.10.079.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarnitineDisease ProgressionEnergy MetabolismExercise TherapyFemaleHeart Failure, SystolicHeart-Assist DevicesHospital MortalityHumansMaleMass SpectrometryMiddle AgedNorth CarolinaOutcome Assessment, Health CarePrognosisReproducibility of ResultsSeverity of Illness IndexStatistics as TopicConceptsEnd-stage heart failureSystolic heart failureHeart failureMechanical circulatory supportHF patientsClinical outcomesCirculatory supportEnd-stage systolic heart failureChronic systolic HF patientsLeft ventricular assist device placementLong-term mechanical circulatory supportVentricular assist device placementPeak VO2 levelsChronic HF patientsSystolic HF patientsAdverse clinical outcomesClinical trial outcomesLong-chain acylcarnitinesAssociations of metabolitesFrozen plasma samplesMechanical circulatoryCardiovascular deathCause hospitalizationCause mortalityLVAD group
2013
Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 525-533. PMID: 24021697, DOI: 10.1161/circoutcomes.111.000079.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCaliforniaCardiotonic AgentsChi-Square DistributionDigoxinDisease ProgressionDrug Therapy, CombinationFemaleGuideline AdherenceHealth Maintenance OrganizationsHeart Failure, SystolicHospitalizationHumansIncidenceMaleMiddle AgedMultivariate AnalysisPractice Guidelines as TopicProportional Hazards ModelsRisk FactorsSex FactorsTime FactorsTreatment OutcomeConceptsIncident systolic heart failureSystolic heart failureSafety of digoxinΒ-blocker useDigoxin useHeart failureHF hospitalizationConcurrent β-blocker useSymptomatic systolic heart failureKaiser Permanente Northern CaliforniaHF disease severityOptimal medical therapyRisk of deathMedical therapyMultivariable analysisContemporary cohortCox regressionClinical guidelinesMedical historyHigh riskHospitalizationHigh mortalityPatientsDisease severityTrial dataMitral Valve Dynamics in Severe Aortic Stenosis before and after Aortic Valve Replacement
Tsang W, Veronesi F, Sugeng L, Weinert L, Takeuchi M, Jeevanandam V, Lang R. Mitral Valve Dynamics in Severe Aortic Stenosis before and after Aortic Valve Replacement. Journal Of The American Society Of Echocardiography 2013, 26: 606-614. PMID: 23602168, DOI: 10.1016/j.echo.2013.03.004.Peer-Reviewed Original ResearchConceptsAortic valve replacementAortic-mitral fibrous continuitySystolic heart failureSevere aortic stenosisFibrous continuityLeft ventricular functionMitral valveAortic stenosisVentricular functionValve replacementHeart failureNormal left ventricular functionThree-dimensional transesophageal echocardiographyNormal valvesSurgical aortic valve replacementProsthetic aortic valveMitral valve functionMA areaProsthetic valve ringPre-AVRCardiac cycleTransesophageal echocardiographyAortic valveValve functionLeft ventricleInfluence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease
Doenst T, Cleland JG, Rouleau JL, She L, Wos S, Ohman EM, Krzeminska-Pakula M, Airan B, Jones RH, Siepe M, Sopko G, Velazquez EJ, Racine N, Gullestad L, Filgueira JL, Lee KL. Influence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease. Circulation Heart Failure 2013, 6: 443-450. PMID: 23515275, PMCID: PMC3721746, DOI: 10.1161/circheartfailure.112.000130.Peer-Reviewed Original ResearchConceptsHeart failureCoronary artery bypass graft surgeryIschemic Heart Failure (STICH) trialPatient/family decisionArtery bypass graft surgeryImpact of CABGBypass graft surgeryHeart Failure TrialMultivariable Cox modelSystolic heart failureCoronary artery diseaseIschemic heart diseaseAcute decompensationGraft surgeryProgressive symptomsArtery diseaseMedical therapySurgical treatmentFailure TrialPatient populationHeart diseaseCABGCommon reasonCox modelPatients
2009
Self-Reported and Actual Beta-Blocker Prescribing for Heart Failure Patients: Physician Predictors
Sinha S, Schwartz MD, Qin A, Ross JS. Self-Reported and Actual Beta-Blocker Prescribing for Heart Failure Patients: Physician Predictors. PLOS ONE 2009, 4: e8522. PMID: 20046824, PMCID: PMC2796176, DOI: 10.1371/journal.pone.0008522.Peer-Reviewed Original ResearchConceptsBeta-blocker prescribingSelf-reported prescribingHF patientsSystolic heart failureHeart failurePhysician characteristicsActual prescribingPrimary care physician characteristicsVeterans Affairs Medical CenterRetrospective chart reviewHeart failure patientsPrimary care providersCross-sectional surveySelf-reported ratesHF carePhysician predictorsChart reviewClinical characteristicsFailure patientsPrescription ratesPrimary carePrescribing dataInpatient wardsPractice patternsMedical Center
2005
Outcomes by Race and Etiology of Patients With Left Ventricular Systolic Dysfunction
Thomas KL, East MA, Velazquez EJ, Tuttle RH, Shaw LK, O’Connor C, Peterson ED. Outcomes by Race and Etiology of Patients With Left Ventricular Systolic Dysfunction. The American Journal Of Cardiology 2005, 96: 956-963. PMID: 16188524, DOI: 10.1016/j.amjcard.2005.07.002.Peer-Reviewed Original ResearchConceptsProportional hazards regression modelsLV systolic dysfunctionVentricular systolic dysfunctionSystolic dysfunctionNonischemic etiologyHeart failureAdjusted Cox proportional hazards regression modelNew York Heart Association class IICox proportional hazards regression modelRacial differencesIschemic LV systolic dysfunctionSignificant coronary artery diseaseLong-term mortality riskWorse long-term outcomesNonischemic LV dysfunctionOutcomes of patientsSystolic heart failureEtiology of patientsLV ejection fractionCoronary artery diseaseLong-term outcomesHazards regression modelsLV dysfunctionWorse survivalArtery diseaseThe Relationship Between B-type Natriuretic Peptide and Health Status in Patients With Heart Failure
Luther SA, McCullough PA, Havranek EP, Rumsfeld JS, Jones PG, Heidenreich PA, Peterson ED, Rathore SS, Krumholz HM, Weintraub WS, Spertus JA, Masoudi FA, Consortium F. The Relationship Between B-type Natriuretic Peptide and Health Status in Patients With Heart Failure. Journal Of Cardiac Failure 2005, 11: 414-421. PMID: 16105631, DOI: 10.1016/j.cardfail.2005.02.004.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy QuestionnaireBNP levelsHeart failureHealth statusBNP changesB-type natriuretic peptide levelsNew York Heart Association classificationB-type natriuretic peptideBaseline BNP levelsKCCQ summary scoreNatriuretic peptide levelsHeart failure severitySystolic heart failureHealth status instrumentsBaseline BNPKCCQ scoresNatriuretic peptideAssociation classificationPatients' perceptionsPeptide levelsPhysiologic measuresSummary scoresPatientsBNPDisease severity
2004
Renal Function, Digoxin Therapy, and Heart Failure Outcomes: Evidence from the Digoxin Intervention Group Trial
SHLIPAK MG, SMITH GL, RATHORE SS, MASSIE BM, KRUMHOLZ HM. Renal Function, Digoxin Therapy, and Heart Failure Outcomes: Evidence from the Digoxin Intervention Group Trial. Journal Of The American Society Of Nephrology 2004, 15: 2195-2203. PMID: 15284305, DOI: 10.1097/01.asn.0000135121.81744.75.Peer-Reviewed Original ResearchConceptsGlomerular filtration rateHeart failure outcomesEffect of digoxinRenal functionHeart failureRenal dysfunctionGroup trialsMortality riskLow glomerular filtration rateLevel of GFRFailure outcomesSystolic heart failureHeart failure survivalLower mortality hazardDigoxin efficacyCause mortalityDigoxin therapyCommon complicationClinical outcomesFiltration rateGFR 60Failure survivalSimilar riskMortality hazardStable outpatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply